Filter News
Area of Research
- (-) Isotopes (5)
- Biological Systems (1)
- Biology and Environment (54)
- Biology and Soft Matter (1)
- Clean Energy (69)
- Climate and Environmental Systems (1)
- Computational Biology (1)
- Computational Engineering (1)
- Computer Science (1)
- Fusion and Fission (9)
- Fusion Energy (1)
- Materials (42)
- Materials for Computing (9)
- National Security (9)
- Neutron Science (15)
- Nuclear Science and Technology (7)
- Supercomputing (53)
Media Contacts
![Seeing the difference Ac-225 could make to cancer patients made Raina Setzer want to come to ORNL to directly work with the isotope. Credit: Allison Peacock/ORNL, U.S. Dept. of Energy](/sites/default/files/styles/list_page_thumbnail/public/2023-11/rs_0.jpg?h=71976bb4&itok=nFsgqwUT)
Raina Setzer knows the work she does matters. That’s because she’s already seen it from the other side. Setzer, a radiochemical processing technician in Oak Ridge National Laboratory’s Isotope Processing and Manufacturing Division, joined the lab in June 2023.
![Jason Gardner, Sandra Davern and Peter Thornton have been elected fellows of AAAS. Credit: Laddy Fields/ORNL, U.S. Dept. of Energy](/sites/default/files/styles/list_page_thumbnail/public/2023-02/AAAS_2022%20Thumbnail_0.png?h=b6717701&itok=4TftuioC)
Three scientists from the Department of Energy’s Oak Ridge National Laboratory have been elected fellows of the American Association for the Advancement of Science, or AAAS.
![Summer Widner, Stephanie Timbs, James Gaugler and James Avenell of ORNL are part of a team that processes thorium-228, a byproduct of actinium-227. As new uses for thorium are realized, particularly in medicine, the lab expects the demand for the radioisotope to grow.](/sites/default/files/styles/list_page_thumbnail/public/2021-08/Part%20of%20Th-228%20Team_1.jpg?h=09b6d1d3&itok=1_l1hx2l)
As a medical isotope, thorium-228 has a lot of potential — and Oak Ridge National Laboratory produces a lot.
![Targeted alpha therapy can deliver radiation to specific cells, with minimal effect on surrounding, healthy cells. Credit: Michelle Lehman and Jaimee Janiga/ORNL, U.S. Dept. of Energy](/sites/default/files/styles/list_page_thumbnail/public/2021-03/gif_high_res.gif?h=ae1281eb&itok=QtNBjm3O)
A rare isotope in high demand for treating cancer is now more available to pharmaceutical companies developing and testing new drugs.
![Sandra Davern performs cell based assays to evaluate cell death and DNA damage in response to radiation in order to gain a better understanding of how radioisotope nanoparticles affect the human body.](/sites/default/files/styles/list_page_thumbnail/public/2020-10/2020-P15712.jpg?h=036a71b7&itok=6cpxN4v2)
When Sandra Davern looks to the future, she sees individualized isotopes sent into the body with a specific target: cancer cells.